Mylan
FULPHILA
Manufacturer:
Mylan
Name:
FULPHILA
HCPCS Code Descriptor:
Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
Category:
Q Code
HCPCS:
Q5108
NDC(s):
67457-0833-06
Primary Type:
Oncology Biosimilar Colony Stimulating Factor
Generic Status:
Single-Source
Route of Administration:
Subcutaneous
About:
FULPHILA is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Mylan and administered via the Subcutaneous route of administration. The Q Code: Q5108 is aligned to the drug FULPHILA.
Fulphila (pegfilgrastim) is used to prevent patients from developing a deficiency of certain white blood cells by aiding in the production of these white blood cells. This medication is manufactured by Mylan Institutional and is a biosimilar to the drug Neulasta (J2506). Patient assistance programs for this medication can be found through the Viatris Patient Assistance program.
Access Pricing and More By Registering
HCPCS Added Date:
10/1/18
HCPCS Effective Date:
4/1/23
HCPCS Short Description:
Injection, fulphila
Billing and Coding Guide:
https://www.viatrisadvocate.com/-/media/viatrisadvocatecom/pdf/fulphila/peg-2019-0149-v3-fulphila-billing-and-coding-guide.pdf
Patient Assistance:
https://www.viatris.com/en-us/lm/united-states/patient-assistance-program
